Intervention

ixabepilone

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 23 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials23

Recruiting0

Common conditions18

Lead sponsors shown14

Clinical trials

23 shown

A Study of LY2523355 in Participants With Breast CancerNCT01416389 · 2011-08-01

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After SurgeryNCT01079793 · 2010-05-26

Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast CancerNCT01084057 · 2010-05-17

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)NCT01057212 · 2010-02-01

Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With ChemotherapyNCT00998101 · 2009-07-01

Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast CancerNCT00765765 · 2009-02-01

Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)NCT00790894 · 2008-11-01

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast CancerNCT00633464 · 2008-06-01

Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast CancerNCT00637897 · 2008-03-01

A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast CancerNCT00490646 · 2008-02-01

Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of NeuronsNCT00627978 · 2007-11-01

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast CancerNCT00630032 · 2007-09-01

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and ChemotherapyNCT00331344 · 2006-04-01

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian CancerNCT00182767 · 2006-01-01

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast CancerNCT00077376 · 2005-03-01

Ixabepilone in Treating Patients With Metastatic Prostate CancerNCT00087139 · 2004-09-01

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast CancerNCT00079326 · 2004-01-01

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate CancerNCT00058084 · 2003-03-01

BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast CancerNCT00049244 · 2002-09-01

Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast CancerNCT00045097 · 2002-05-01

Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate CancerNCT00025194 · 2001-07-01

BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyNCT00016393 · 2001-06-01

BMS-247550 in Treating Women With Metastatic Breast CancerNCT00020904 · 2001-02-01

Common conditions

Breast Cancer6 Metastatic Breast Cancer5 Recurrent Breast Cancer4 Stage IV Breast Cancer4 Adenocarcinoma of the Prostate3 Prostate Cancer3 Recurrent Prostate Cancer3 Stage IV Prostate Cancer3 HER2-positive Breast Cancer2 Male Breast Cancer2 Fallopian Tube Cancer1 Female Reproductive Cancer1 Lung Cancer1 Non-squamous Non-small Cell Lung Cancer1 Recurrent Ovarian Epithelial Cancer1 Stage III Ovarian Epithelial Cancer1 Stage IV Ovarian Epithelial Cancer1 Triple Negative Locally Advanced Non-resectable Breast Cancer1

Leading sponsors

National Cancer Institute (NCI) 7 R-Pharm 3 Memorial Sloan Kettering Cancer Center 2 City of Hope Medical Center 1 Eli Lilly and Company 1 Hellenic Cooperative Oncology Group 1 Providence Health & Services 1 SWOG Cancer Research Network 1 UNC Lineberger Comprehensive Cancer Center 1 UNICANCER 1 University of Medicine and Dentistry of New Jersey 1 University of Texas Southwestern Medical Center 1 Wake Forest University Health Sciences 1 Weill Medical College of Cornell University 1

Trial status mix

COMPLETED16

TERMINATED4

WITHDRAWN2

UNKNOWN1

Phase mix

PHASE219

PHASE18

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.